Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

NCT02125240 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Positive Non-small Cell Lung Cancer
Adenocarcinoma

Interventions

DRUG: Icotinib
DRUG: Placebo

Sponsor

Betta Pharmaceuticals Co., Ltd.